Press coverage about Zosano Pharma (NASDAQ:ZSAN) has trended positive on Wednesday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zosano Pharma earned a news sentiment score of 0.28 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.4947059058239 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of Zosano Pharma (NASDAQ ZSAN) traded down $1.14 during mid-day trading on Wednesday, hitting $3.66. The stock had a trading volume of 330,500 shares, compared to its average volume of 80,093. The firm has a market capitalization of $9.47, a price-to-earnings ratio of -0.16 and a beta of 1.90. Zosano Pharma has a fifty-two week low of $3.61 and a fifty-two week high of $70.80.
Separately, ValuEngine raised Zosano Pharma from a “strong sell” rating to a “sell” rating in a report on Wednesday, February 7th.
In related news, Director Kenneth Greathouse bought 55,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 6th. The shares were purchased at an average cost of $0.61 per share, with a total value of $33,550.00. Following the completion of the acquisition, the director now directly owns 200,000 shares in the company, valued at $122,000. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.83% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This report was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://ledgergazette.com/2018/02/14/positive-media-coverage-somewhat-unlikely-to-impact-zosano-pharma-zsan-share-price.html.
Zosano Pharma Company Profile
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.